GlassScriptPhysician profile
Marc Lozano
NPI 1841827532
$1,972.36
in general payments reported to CMS, 2019-2025
14 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $275 · 2024: $833 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,952.14 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $312.26 | 2025 | Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $302.70 | 2024-2025 | |
| Corcept Therapeutics | $300.03 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $271.02 | 2024-2025 | |
| Amgen INC. | $209.08 | 2024-2025 | Tepezza, Evenity |
| Astrazeneca Pharmaceuticals LP | $138.85 | 2023 | Airsupra |
| Medtronic, INC. | $109.89 | 2024 | Minimed 780g |
| Merck Sharp & Dohme LLC | $106.72 | 2023 | |
| Radius Health, INC. | $86.49 | 2025 | Tymlos |
| Recordati_rare_diseases_inc. | $44.24 | 2024-2025 | Isturisa, Signifor Lar |
| Mannkind Corporation | $29.22 | 2023 | Afrezza |
| Insulet Corporation | $27.43 | 2025 | Omnipod |
| Sequel Med Tech, LLC | $17.40 | 2025 | Twiist |
| Lilly USA, LLC | $17.03 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Lozano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.